2 Top Tech Stocks to Buy Before they Soar in the Second Half
The upbeat day might signal that investors are learning lessons from the initial trade war fears, betting that Trump and his administration likely do not want to crush the U.S. economy or the stock market.
Investors could still take profits on high-flying tech stocks heading into Q2 earnings season.
Thankfully, the bulls should remain in charge as long as AI and tech-boosted earnings growth holds up. Plus, the Fed is still projected to cut interest rates again in 2025.
Now might be a good time for investors to start buying tech stocks that are trading well below their all-time highs before they possibly surge in July and beyond.
Lumentum LITE designs and manufactures optical and photonic technologies for high-speed telecommunications, data centers, and advanced manufacturing. LITE provides components, such as transceivers and lasers for fiber-optic networks, supporting the rapid growth of artificial intelligence, cloud computing, 5G connectivity, and beyond.
Its industrial lasers are used in precision manufacturing, such as cutting semiconductors and solar cells. Lumentum also develops 3D sensing laser diodes for applications like facial recognition in smartphones and autonomous vehicle sensors. Despite this backdrop, Lumentum stock only climbed 10% in the past five years while the Tech sector soared 110%.
Image Source: Zacks Investment Research
Lumentum's revenue growth plateaued after 2019, driven by multiple headwinds. LITE announced in May 2019 that it had discontinued all shipments to Huawei after the U.S. government forced tech companies to stop supplying the Chinese smartphone maker due to national security concerns.
Wall Street also grew worried about Lumentum's overreliance on Apple for its growth in a slowing iPhone market. On top of that, Covid-based inventory corrections, macroeconomic pressures such as inflation, and trade restrictions dragged LITE down over the past several years.
Thankfully for investors, Lumentum is turning the corner, boosted by surging AI demand. Lumentum crushed our EPS estimate by an average of 42% in the trailing four quarters, including a big beat-and-raise Q3 FY25 in early May. Its upbeat earnings revisions land LITE a Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Lumentum's next-generation optics are helping create energy-efficient AI networks, which is critical in the power-hungry AI space. New CEO Michael Hurlston, who took over in February, said LITE's innovations are 'driving transformative power efficiencies across cloud, AI, and long-haul networks, making us an essential partner in this next era of connectivity.'
LITE is projected to grow its revenue by 20% in FY25 and 33% next year to surge from $1.36 billion in FY24 to $2.17 billion in FY26, crushing its previous peaks. Better yet, the tech innovator is projected to double its adjusted EPS in FY25 (+95%) and FY26 (+111%) to reach $4.16 a share. Some of Lumentum's growth is driven by its late-2023 acquisition of Cloud Light Technology.
Image Source: Zacks Investment Research
Lumentum shares have kept pace with Tech over the past decade despite its huge underperformance over the last five years. The stock is neck and neck with Tech in 2025 and up 60% in the past year to crush its sector's 8% run. LITE completed a long-term golden cross, where its 50-week moving average overtook its 200-week, in May.
A strong earnings report could help it finally break out above its 2021 peaks after several failed attempts. Lumentum stock also trades at a 40% discount to Tech on the price/earnings to growth ratio front.
Customer relationship management standout HubSpot HUBS posted blockbuster growth over the last decade as companies big and small race to digitalize every pocket of their businesses. HUBS stock has roughly tripled the Tech sector during that stretch, fueled by massive growth that took it from $182 million in 2015 revenue to $2.6 billion last year.
Despite outrunning Tech in the last three and five-year stretches, HUBS trades 30% below its highs even as the Tech sector ripped to fresh records to close the first half. HubSpot stock cooled on the back of slowing sales growth compared to its days of 30% to 50% expansion and its inability to consistently post profits.
Yet, HubSpot could be ready to break out and return to all-time highs given its robust adjusted earnings and revenue growth outlook.
Image Source: Zacks Investment Research
HubSpot's solutions are designed to help its clients attract customers, build relationships, and keep them happy. The business software company launched its Breeze artificial intelligence platform last year, integrating HubSpot's AI tools throughout its entire CRM platform.
Its AI-powered customer platform helps businesses grow by managing marketing, sales, customer service, content, operations, and beyond more efficiently than ever before.
Image Source: Zacks Investment Research
The Cambridge, Massachusetts-based company is projected to expand its revenue by roughly 16% in 2025 and 2026 to reach $3.51 billion, adding nearly $1 billion to its top line vs. 2024. It is expected to grow its adjusted earnings by 15% and 21%, respectively. HUBS has beaten our quarterly earnings estimates for five years in a row, and its recent upward earnings revisions earn it a Zacks Rank #1 (Strong Buy).
HubSpot trades 30% below its 2021 highs after getting firmly rejected at those levels in February. HUBS stock is trading right near its 21-day moving average, and it's held its ground at or near its long-term 200-week moving average several times in the past year.
The 200-week moving average was one of Warren Buffett's longtime right-hand man, Charlie Munger's, favorite technical indicators for buying long-term stocks.
Image Source: Zacks Investment Research
It might be worth taking a chance on HubSpot for near-term upside to its peaks and long-term AI-boosted growth. Plus, the company's robust balance sheet is helping it buy back stock. Wall Street is also still very high on the stock, with 26 of the 33 brokerage recommendations Zacks has at 'Strong Buys.'
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HubSpot, Inc. (HUBS) : Free Stock Analysis Report
Lumentum Holdings Inc. (LITE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Wells Fargo Stock Slides as Bank Lowers Its Outlook for a Key Measure of Profitability
Wells Fargo (WFC) on Tuesday lowered its outlook for net interest income, a key measure of profitability, sending shares lower in premarket trading. Wells Fargo cut its guidance for 2025 net interest income "to be roughly in line" with its 2024 net interest income of $47.7 billion, from its previous forecast of 1% to 3% growth. Net interest income for the second quarter fell to $11.71 billion from $12.02 billion a year ago—below the $11.84 billion analysts anticipated. The lender reported second-quarter adjusted earnings per share (EPS) of $1.6 on revenue that rose to $20.82 billion from $20.69 billion, above analysts' estimates. The results come after the Federal Reserve last month lifted curbs on the bank's growth imposed seven years ago following a series of scandals, including one where staff set up fake accounts. 'The lifting of the asset cap in the second quarter marked a pivotal milestone in Wells Fargo's ongoing transformation, along with the termination of thirteen consent orders since 2019, including seven this year alone," CEO Charlie Scharf said in a release. Wells Fargo shares, which entered Tuesday up about 19% this year, were down close to 4% in premarket trading. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Radancy Announces the Next Evolution of Its AI Platform - Redefining How the World Hires with Agentic AI
NEW YORK, July 15, 2025 /PRNewswire/ -- Radancy, the global leader in talent acquisition software, today announced the next evolution of the Radancy Talent Acquisition Cloud – an AI-powered platform that transforms how the world hires. Fueled by Agentic AI and insights drawn from the world's largest talent dataset, with billions of interactions, the platform sets a new standard in intelligent hiring – delivering smarter, more cost-effective strategies, better-fit candidates and measurable impact at every stage of the hiring journey. As candidate expectations, skill demands, budget constraints and workforce dynamics shift rapidly, Radancy's next-generation platform replaces fragmented recruiting processes with a seamless, intelligent and adaptive hiring experience. From the first brand interaction to final application, the platform acts with real-time context and intent – empowering organizations to connect with top talent faster, more precisely and more efficiently than ever before. This is more than an upgrade – it's a transformation. The platform equips recruiters with predictive insights and intelligent automation, delivers highly personalized, conversational candidate journeys and embeds real-time intelligence into every interaction. Features like natural language search, dynamic role previews and context-aware AI agents make hiring decisions easier and more effective across the entire process. "Radancy is ushering in a new era of intelligent hiring – where technology doesn't just streamline the process, it elevates it," said Michelle Abbey, President and CEO of Radancy. "Our platform is engineered to connect the right talent to the right roles at the right time – and deliver business results that matter." Every candidate interaction sharpens its ability to anticipate, adapt and act – bridging employer needs with candidate potential and driving optimized performance through embedded analytics. The result: accelerated hiring cycles, reduced costs, less friction and a more meaningful experience for all stakeholders. Built for global scale, flexibility and results, the Radancy Talent Acquisition Cloud combines deep industry expertise, ethical AI principles and a unified experience across the reimagined hiring journey. Robust data security, compliance and governance are embedded into the core of the platform – ensuring enterprises meet evolving regulatory standards while safeguarding privacy and trust. With an unwavering commitment to support, innovation and ROI, Radancy empowers enterprises to build the workforce of tomorrow – with clarity, confidence and competitive advantage. About RadancyRadancy delivers the future of hiring. As the global leader in talent acquisition software, Radancy helps enterprises strengthen their organizations with an AI-powered platform that simplifies hiring, reduces costs and accelerates results. Fueled by rich data and deep industry expertise, the Radancy Talent Acquisition Cloud transforms every step of the candidate journey to hire the most qualified talent in any environment – driving efficiency, enhancing experiences, maximizing ROI and empowering organizations to build the workforce of tomorrow. Learn more at View original content: SOURCE Radancy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best low priced pharma stocks to buy now. From June 20 to 23, Wave Life Sciences presented preclinical data for WVE-007, which is its investigational GalNAc-siRNA targeting INHBE mRNA, at the American Diabetes Association's 85th Annual Scientific Sessions in Chicago. The oral presentation was delivered on June 21 and highlighted WVE-007 as a potential novel and distinct obesity treatment designed to induce healthy weight loss by reducing fat while preserving muscle mass. WVE-007 functions by silencing INHBE mRNA, which in turn reduces the production of Activin E protein. Activin E is a lipolysis suppressor that is upregulated in obesity. By inhibiting Activin E, WVE-007 promotes lipolysis, or fat breakdown. A biotechnology laboratory filled with computers and equipment to support research. Human genetics provides strong support for INHBE as a therapeutic target. Individuals with a protective loss-of-function variant in one copy of the INHBE gene exhibit a healthier cardiometabolic profile, which includes less abdominal fat, lower triglycerides, and reduced risk of type 2 diabetes/T2D and cardiovascular disease/CAD. These individuals also show favorable associations with liver traits, such as reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), without impacting liver fat. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that designs, develops, and commercializes ribonucleic acid/RNA medicines through PRISM, which is a discovery and drug development platform. While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data